glp 1 rebound weight gain A Comprehensive Review on following Discontinuation of Glucagon-Like Peptide-1 Receptor Agonists for Obesity Does stopping GLP-1s make you

Blend yogurt, berries, agave, and Replenza until smooth

A study presented recently at ARVO 2026 analyzed the incidence of glaucoma, macular and ophthalmic diseases over a four-year period among non-diabetic adults prescribed GLP-1 drugs and found these medications provide a variety of protective signals

Roche announces positive Phase II results for petrelintide, an amylin analog developed for people living with overweight and obesity

Major health plans and PBMs have built institutional knowledge of how to structure formulary decisions, step therapy requirements, and prior authorization criteria to accelerate biosimilar adoption and have financial incentives to deploy that knowledge more aggressively than in the adalimumab cycle

Retatrutide is at the Phase 3 stage, and the cagrilintide-plus-semaglutide combination CagriSema was reported to have a New Drug Application under FDA review, but a filing under review is not an approval

Up-regulated CD38 by daphnetin alleviates lipopolysaccharide-induced lung injury via inhibiting MAPK/NF-B/NLRP3 pathway